Effect of Astragalus Membranaceus on the Improvement of Cognitive Function in Alzheimer's Disease

Overview

Alzheimer's disease (AD), the most common cause of dementia, is characterized by cognitive impairment, mental and behavioural abnormalities, and social dysfunction. Current treatments can only delay the progression of AD, not cure it completely. In vitro studies have shown that Astragalus has toxic effects such as anti-hypoxia injury of nerve cells, anti-free radical damage, anti-excitatory amino acids, etc. It can be used to expand cerebral vessels, increase cerebral blood flow, improve cerebral microcirculation, protect brain cells, and repair damaged brain cells. However, the clinical effects of add-on Astragalus in improving cognition in these patients remain unclear. Therefore, this pragmatic clinical trial aims to determine the efficacy and safety of add-on Astragalus in improving cognition in patients with AD

Eligibility

Inclusion Criteria:Participants with a clinical diagnosis of Alzheimer's disease.

-

Exclusion Criteria:Patients who have one of the following were excluded from this trial:

1. being treated or history of serious diseases such as stroke or transient ischemic attack, claustrophobia, bipolar disorder, schizophrenia, seizures, drug or alcohol abuse, malignancy, renal failure and dialysis treatment, liver disease (hepatitis), renal disease.
2. unable to have magnetic resonance imaging (MRI) or electroencephalogram (EEG).
3. use of health foods, supplements, and medicines that may affect cognitive function,
4. have severe visual and/or hearing impairment.
5. during pregnancy or lactation
6. participation in other clinical studies within the past 3 months. -